查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470918

黑色素瘤治療藥物市場：按類型、產品和分銷管道分類 - 全球預測 2024-2030

Melanoma Drug Market by Type (Acral Lentiginous Melanoma, Lentigo Maligna Melanoma, Nodular Melanoma), Product (Adjuvant Therapy, Biochemotherapy, Chemotherapy Drugs), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年黑色素瘤治療市場規模為54億美元，2024年預估達58.1億美元，2030年將達94.5億美元，複合年成長率為8.32%。

黑色素瘤藥物是一組專門用於治療黑色素瘤（一種皮膚癌）的藥物。這些藥物分為多種類型，包括免疫療法、標靶治療、化療和溶瘤病毒療法。全球黑色素瘤盛行率的不斷上升正在推動治療藥物的創新。此外，政府對醫療保健產業投資的增加和報銷政策的擴大正在推動市場成長。然而，與藥物開發和治療相關的高成本正在影響市場成長。嚴格的監管政策和漫長的核准流程阻礙了持續的研發活動。此外，由於副作用減少和效率高，對標靶治療的需求不斷成長，這為市場成長提供了重要機會。

主要市場統計
基準年[2023] 54億美元
預測年份 [2024] 58.1億美元
預測年份 [2030] 94.5億美元
複合年成長率（%） 8.32%

肢端雀斑樣黑色素瘤和惡性雀斑樣痣黑色素瘤對非侵入性治療的需求不斷增加

肢端雀斑樣黑色素瘤 (ALM) 是黑色素瘤中最不常見的亞型，通常發生在手掌、腳底和指甲下方。對此類藥物的需求是由於它們的診斷緩慢且由於缺乏明顯的警告訊號而難以治療。惡性雀斑樣黑色素瘤 (LMM) 常見於有長期日曬史的老年人。該領域的藥物通常關注腫瘤的分子和遺傳特徵，因為它們往往生長緩慢且淺表。結節性黑色素瘤 (NM) 以其快速、侵襲性生長而聞名，通常在幾個月內侵入皮膚深層。最終使用者優先考慮有可能減少結節並改善手術效果的速效治療方法。表淺擴散性黑色素瘤 (SSM) 是最常見的黑色素瘤類型，通常表現為擴散到皮膚的痣。 SSM 的藥物選擇通常包括具有預防和長期管理功能的藥物，以及可以解決轉移的治療方法。

產品對治療黑色素瘤疾病進展和基因突變的下一代藥物的需求不斷增加

黑色素瘤的術後輔助性治療是指在手術等主要治療後進行的治療，以去除殘留病灶並降低復發風險。常見的輔助性治療包括免疫治療和標靶治療。化療將化療與生物治療結合起來治療黑色素瘤患者。當黑色素瘤已經轉移且其他治療方法不夠有效時，就需要這種治療。這是一種更積極的治療方法，通常在疾病處於晚期時才考慮。Dacarbazine等化療藥物歷來被用於治療轉移性黑色素瘤，但這些藥物很大程度上已被更新的治療方法所取代。它主要用於其他治療方法禁忌或腫瘤不具有可操作突變的情況。免疫治療藥物，例如查核點抑制劑，可以提高免疫系統檢測和破壞癌細胞的能力。它通常用於晚期黑色素瘤，包括不可切除或轉移性黑色素瘤。溶瘤病毒療法使用基因工程病毒選擇性地感染和破壞癌細胞。對於具有可注射病變和有限擴散的患者，通常首選這種治療方法。分子標靶治療作用於與癌症相關的特定分子標靶，對於腫瘤具有可識別基因突變（例如 BRAF V600 突變）的患者來說是首選。這些藥物徹底改變了轉移性黑色素瘤的治療模式。

分銷管道：由於便利性和遠端醫療支持，對線上管道的需求增加

黑色素瘤藥物的線下分銷管道主要包括醫院藥房、零售藥房和診所。這些傳統管道因其涵蓋範圍廣、患者容易獲得以及直接獲得專業醫療建議和諮詢而成為藥品分銷的支柱。由於技術進步和消費者偏好的變化，黑色素瘤治療的線上分銷管道正在迅速成長。線上藥局和藥品配送服務在數位平台的支援下為患者提供送貨上門的便利，實現處方箋管理、提醒和遠端醫療諮詢。線下管道可以直接獲得專家指導並立即獲得藥品，這對於急需治療的患者至關重要。相反，線上管道提供便利、價格實惠，並且能夠覆蓋更廣泛的地理患者群體。

區域洞察

美洲皮膚癌發生率很高，這使其成為黑色素瘤治療的重要市場。先進的醫療基礎設施、對黑色素瘤的高度認知和報銷政策促進了強勁的消費者需求。美國黑色素瘤治療市場受到標靶治療和免疫治療創新的推動，並得到 FDA 加速核准有前途的治療方法的支持。患者援助計劃和保險範圍通常會影響客戶的購買行為。歐洲黑色素瘤藥物市場受到嚴格監管，重點是高效且具成本效益的治療方法。由於黑色素瘤患者數量的增加和完善的醫療保健系統的存在，歐盟 (EU) 國家表現出很高的消費者需求。新治療方法的採用受到歐洲藥品管理局 (EMA) 和衛生技術評估 (HTA) 機構法規的影響，該機構負責評估新藥的價值。黑色素瘤舉措。中東國家對醫療保健的投資不斷增加，對創新治療的需求不斷成長。亞太地區黑色素瘤患者的數量正在迅速增加，中國、日本和印度等國家對不斷成長的消費需求做出了巨大貢獻。在亞太地區，醫療保健和創新投資的增加開始重塑市場。亞太地區黑色素瘤治療市場受益於政府措施和臨床試驗中強大的治療管道的結合。

FPNV定位矩陣

FPNV定位矩陣對於評估黑色素瘤藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對黑色素瘤治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.黑色素瘤治療藥物市場的市場規模和預測是多少？

2.黑色素瘤治療藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.黑色素瘤治療藥物市場的技術趨勢和法規結構是什麼？

4.黑色素瘤治療藥物市場主要供應商的市場佔有率是多少？

5.進入黑色素瘤藥物市場的合適形式和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球黑色素瘤和其他皮膚癌的發生率不斷上升
      • 政府增加醫療保健支出
      • 推動腫瘤領域生物相似藥的發展
    • 抑制因素
      • 藥物開發和治療成本高昂
    • 機會
      • 對副作用更少、效率更高的標靶治療的需求不斷增加
      • 繼續進行旨在推出有效藥物的研究和開發活動
    • 任務
      • 嚴格的監管政策和漫長的核准流程
  • 市場區隔分析
    • 類型：肢端惡性黑色素瘤和惡性雀斑樣痣惡性黑色素瘤對非侵入性治療方法的需求不斷增加
    • 產品：對治療惡性黑色素瘤疾病進展和基因突變的下一代藥物的需求增加
    • 分銷管道：由於便利和遠端醫療支持，對線上管道的需求不斷成長
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章黑色素瘤治療藥物市場：依類型

  • 肢端雀斑樣黑色素瘤
  • 惡性雀斑
  • 結節性黑色素瘤
  • 表淺黑色素瘤

第7章黑色素瘤治療藥物市場：依產品

  • 輔助性治療
  • 化療
  • 化療藥物
  • 免疫治療藥物
  • 溶瘤病毒療法
  • 標靶治療

第8章黑色素瘤治療藥物市場：按分銷管道

  • 離線
  • 線上

第9章北美和南美黑色素瘤藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太黑色素瘤藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲黑色素瘤藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Moderna 和默克公司宣布，mRNA-4157 (V940) 和 KEYTRUDA (Pembrolizumab) 的組合將改善高風險 III/IV 期惡性患者的 3 年無復發生存率和免於完全切除的生存率。 ，遠處轉移存活率。
    • Sun Pharma 和 Philogen 的黑色素瘤治療在 3 期試驗中顯示出有希望的結果
    • 美國食品藥物管理局核准Opdivo （nivolumab）作為合格的IIB 期或 IIC 期惡性完全切除患者的輔助性治療
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-0363DFE03682

[194 Pages Report] The Melanoma Drug Market size was estimated at USD 5.40 billion in 2023 and expected to reach USD 5.81 billion in 2024, at a CAGR 8.32% to reach USD 9.45 billion by 2030.

Melanoma drugs are a class of pharmaceutical agents specifically designed to treat melanoma, a type of skin cancer. These drugs can be categorized into various types, including immunotherapies, targeted therapies, chemotherapy, and oncolytic virus therapy. Increasing prevalence of melanoma globally, driving innovations in therapeutics. In addition, growing government investments in the healthcare sector and the expansion of reimbursement policies drive market growth. However, the high costs associated with drug development and treatment impact the market growth. Stringent regulatory policies and lengthy approval processes create hindrances to ongoing research and development activities. Furthermore, emerging need for targeted therapy owing to reduced side effects and higher efficiency poses significant opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 5.40 billion
Estimated Year [2024] USD 5.81 billion
Forecast Year [2030] USD 9.45 billion
CAGR (%) 8.32%

Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma

Acral Lentiginous Melanoma (ALM) is the least common subtype of melanoma, typically occurring on the palms, soles, or under the nails. The need for drugs in this category stems from its late diagnosis and the difficulty in treatment due to the lack of visible warning signs. Lentigo Maligna Melanoma (LMM) is commonly found in elderly patients with a history of chronic sun exposure. The drugs in this segment often focus on the molecular and genetic profiles of tumors since they tend to grow slowly and superficially. Nodular Melanoma (NM) is known for its rapid and aggressive growth, often invading deeper layers of the skin within months. End-users prioritize rapid-acting therapies with the potential to shrink nodules and improve surgical outcomes. Superficial Spreading Melanoma (SSM) is the most common type of melanoma, usually presenting as a spreading mole on the skin. Drug preferences for SSM typically involve medications with preventive and long-term management capabilities alongside treatments that can address metastasis.

Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma

Adjuvant therapy in melanoma refers to treatments given after primary therapies, such as surgery, with the intent to eliminate residual disease and reduce the risk of relapse. Common adjuvant therapies include immunotherapies and targeted therapies. Biochemotherapy combines biological treatment with chemotherapy for melanoma patients. The need for this therapy arises when melanoma has spread and is not responding well to other treatments. It is a more aggressive treatment option and is often considered when the disease is in an advanced stage. Chemotherapy drugs, such as dacarbazine, have historically been used for treating metastatic melanoma but have now largely been replaced by newer therapies. The preference arises primarily when other treatment options are contraindicated or the tumor does not harbor actionable mutations. Immunotherapy drugs, such as checkpoint inhibitors, improve the immune system's ability to detect and destroy cancer cells. Their preference is typically for advanced melanoma, including unresectable and metastatic stages. Oncolytic virus therapy employs genetically modified viruses that selectively infect and destroy cancer cells. Preference for this therapy typically arises for patients with injectable lesions and limited disease spread. Targeted therapy drugs act on specific molecular targets associated with cancer and are preferred for patients with identifiable genetic mutations in their tumors, such as BRAF V600 mutations. These drugs have transformed the treatment landscape for metastatic melanoma.

Distribution Channel: Rising demand of online channel due to convenience and telehealth support

Offline distribution channels for melanoma drugs predominantly include hospital pharmacies, retail pharmacies, and clinics. These traditional channels have been the backbone of pharmaceutical distribution due to their wide reach, patient accessibility, and capability to provide in-person professional medical advice and consultation. The online distribution channel for melanoma drugs is rapidly growing, facilitated by technological advances and changing consumer preferences. Online pharmacies and drug delivery services offer patients the convenience of home delivery, often with the support of digital platforms that allow for prescription management, reminders, and telehealth consultations. Offline channels offer in-person professional guidance and immediate access to medication, which is crucial for patients in urgent need of treatment. Conversely, online channels provide convenience, lower prices, and the ability to reach a wider geographic patient base.

Regional Insights

The Americas have a significant market for melanoma drugs due to a higher incidence of skin cancer. Advanced healthcare infrastructure, high awareness regarding melanoma, and reimbursement policies contribute to robust consumer needs. In the United States, the melanoma drug market is driven by innovation in targeted therapies and immunotherapies, supported by the FDA's expedited approvals for promising treatments. Patient assistance programs and insurance coverage often influence customer purchasing behavior. Europe's melanoma drug market is highly regulated, with an emphasis on efficacious and cost-effective treatments. The European Union (EU) countries exhibit high consumer needs due to increasing melanoma cases and the presence of well-established healthcare systems. The adoption of new treatments is influenced by European Medicines Agency (EMA) regulations and HTA (Health Technology Assessment) bodies that assess the value of new medications. European Union initiatives supporting the ongoing research and development activities in melanoma drugs. Middle Eastern countries exhibit growing investment in healthcare and a rising need for innovative treatments. The Asia Pacific region is experiencing a surge in melanoma cases, with countries including China, Japan, and India contributing significantly to rising consumer needs. In APAC, increased investment in healthcare and innovation has begun to reshape the market. Melanoma drug market in APAC benefits from a combination of government initiatives and a strong pipeline of treatments in clinical trials.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Melanoma Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Melanoma Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Melanoma Drug Market, highlighting leading vendors and their innovative profiles. These include AB Science, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, CK Life Sciences Int'l., (Holdings) Inc., Clinigen Group PLC, Eli Lilly and Company, Enzon Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Immunocore Limited, Merck KGaA, Moderna, Inc, Novartis AG, Pfizer, Inc., Philogen S.p.A., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Wellona Pharma.

Market Segmentation & Coverage

This research report categorizes the Melanoma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Acral Lentiginous Melanoma
    • Lentigo Maligna Melanoma
    • Nodular Melanoma
    • Superficial Spreading Melanoma
  • Product
    • Adjuvant Therapy
    • Biochemotherapy
    • Chemotherapy Drugs
      • Dacarbazine (DTIC-Dome)
      • Temozolomide (Temodar)
    • Immunotherapy Drugs
      • Checkpoint Inhibitors
      • CTLA-4 Inhibitors
    • Oncolytic Virus Therapy
    • Targeted Therapy Drugs
      • BRAF Inhibitors
      • MEK Inhibitors
  • Distribution Channel
    • Offline
      • Hospital Pharmacies
      • Retail Pharmacies
    • Online
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Melanoma Drug Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Melanoma Drug Market?

3. What are the technology trends and regulatory frameworks in the Melanoma Drug Market?

4. What is the market share of the leading vendors in the Melanoma Drug Market?

5. Which modes and strategic moves are suitable for entering the Melanoma Drug Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of melanoma and other skin cancers globally
      • 5.1.1.2. Increase in government expenditures on healthcare
      • 5.1.1.3. Elevated development of biosimilar in oncology arena
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with drug development and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging need for targeted therapy owing to reduced side effects and higher efficiency
      • 5.1.3.2. Ongoing research and development activities to introduce effective drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies and lengthy approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising demand of non-invasive therapies across acral lentiginous melanoma and lentigo maligna melanoma
    • 5.2.2. Product: Boost in demand for next generation drugs to treat disease progression and genetic mutations in Melanoma
    • 5.2.3. Distribution Channel: Rising demand of online channel due to convenience and telehealth support
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Melanoma Drug Market, by Type

  • 6.1. Introduction
  • 6.2. Acral Lentiginous Melanoma
  • 6.3. Lentigo Maligna Melanoma
  • 6.4. Nodular Melanoma
  • 6.5. Superficial Spreading Melanoma

7. Melanoma Drug Market, by Product

  • 7.1. Introduction
  • 7.2. Adjuvant Therapy
  • 7.3. Biochemotherapy
  • 7.4. Chemotherapy Drugs
  • 7.5. Immunotherapy Drugs
  • 7.6. Oncolytic Virus Therapy
  • 7.7. Targeted Therapy Drugs

8. Melanoma Drug Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
  • 8.3. Online

9. Americas Melanoma Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Melanoma Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Melanoma Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
    • 12.3.2. Sun Pharma and Philogen's Melanoma Drug Shows Promising Outcome in Phase 3 Trial
    • 12.3.3. U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. MELANOMA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MELANOMA DRUG MARKET DYNAMICS
  • FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY ACRAL LENTIGINOUS MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY LENTIGO MALIGNA MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY NODULAR MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY SUPERFICIAL SPREADING MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL MELANOMA DRUG MARKET SIZE, BY BIOCHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL MELANOMA DRUG MARKET SIZE, BY DACARBAZINE (DTIC-DOME), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY TEMOZOLOMIDE (TEMODAR), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL MELANOMA DRUG MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 109. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 110. CANADA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 117. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 118. CANADA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 122. MEXICO MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 123. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 124. MEXICO MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 129. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 132. MEXICO MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. UNITED STATES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 138. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 143. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 146. UNITED STATES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 147. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 148. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 165. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 170. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 172. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 174. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 178. AUSTRALIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 179. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. CHINA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 182. CHINA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 183. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 184. CHINA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 185. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 186. CHINA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 187. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 188. CHINA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 189. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. CHINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 192. CHINA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 193. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. INDIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. INDIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 198. INDIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 199. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 200. INDIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 201. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 202. INDIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 203. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 204. INDIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 205. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 206. INDIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 207. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. INDONESIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 210. INDONESIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 211. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 212. INDONESIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 213. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 214. INDONESIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 215. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 216. INDONESIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 217. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. INDONESIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 220. INDONESIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 221. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. JAPAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 224. JAPAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 225. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 226. JAPAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 227. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 228. JAPAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 229. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 230. JAPAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 231. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. JAPAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 234. JAPAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 235. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 238. MALAYSIA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 239. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 240. MALAYSIA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 241. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 242. MALAYSIA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 243. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 244. MALAYSIA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 245. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 246. MALAYSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 247. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 248. MALAYSIA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 249. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 252. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 253. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 254. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 255. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 256. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 257. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 258. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 262. PHILIPPINES MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 263. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. SINGAPORE MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 268. SINGAPORE MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 269. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 270. SINGAPORE MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 271. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 272. SINGAPORE MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 273. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. SINGAPORE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 276. SINGAPORE MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 277. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 280. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 281. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 282. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 283. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 284. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 285. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 286. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 287. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 288. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 290. SOUTH KOREA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 291. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. TAIWAN MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 294. TAIWAN MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 295. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 296. TAIWAN MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 297. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 298. TAIWAN MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 299. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 300. TAIWAN MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 301. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 302. TAIWAN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 303. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 304. TAIWAN MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 305. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. THAILAND MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. THAILAND MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 310. THAILAND MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 311. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 312. THAILAND MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 313. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 314. THAILAND MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 315. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 316. THAILAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 317. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 318. THAILAND MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 319. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. VIETNAM MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 322. VIETNAM MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 323. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 324. VIETNAM MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 325. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 326. VIETNAM MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 327. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 328. VIETNAM MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 329. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 330. VIETNAM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 331. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 332. VIETNAM MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 335. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 336. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 338. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 339. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 340. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 341. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 342. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 343. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 344. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 345. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
  • TABLE 346. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
  • TABLE 347. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 348. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 349. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. DENMARK MELANOMA DRUG MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 352. DENMARK MELANOMA DRUG MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 353. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 354. DENMARK MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 355. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 356. DENMARK MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 357. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 358. DENMARK MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 359. DENMARK MELANOMA DR